SCHEMBL6207370

SCHEMBL6207370

O=C(O)Oc1ccc(-c2ccc(F)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 2/20 0.54
BAD Q92934 1/20 0.54
HSD17B10 Q99714 1/20 0.50
KIF11 P52732 1/20 0.43
KMT2A Q03164 3/20 0.42
LMNA P02545 3/20 0.42
ATM Q13315 1/20 0.42
GAA P10253 1/20 0.42
PTPN1 P18031 1/20 0.41
MCL1 Q07820 1/20 0.41
NR4A2 P43354 1/20 0.41
MEN1 O00255 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14389790 0.93 KMT2A (0.46) BCL2L1BADHSD17B10KMT2ALMNA
SCHEMBL27468272 0.91 KMT2A (0.44) BCL2L1BADHSD17B10KMT2ALMNA
SCHEMBL2637327 0.89 HSD17B10 (0.59) HSD17B10KIF11KMT2ALMNAGAA
SCHEMBL194962 0.89 HSD17B10 (0.59) HSD17B10KIF11KMT2ALMNAGAA
SCHEMBL22083773 0.85 HSD17B10 (0.63) BCL2L1BADHSD17B10KMT2ALMNA
Guanidine SCHEMBL6814628 0.83 KMT2A (0.44) KMT2AATMNR4A2
SCHEMBL2760661 0.82 KMT2A (0.55) HSD17B10KMT2ALMNAGAAMEN1
SCHEMBL17714039 0.82 KMT2A (0.55) HSD17B10KMT2ALMNAGAAMEN1
SCHEMBL31109007 0.81 KIF11 (0.65) BCL2L1BADHSD17B10KIF11KMT2A
SCHEMBL465132 0.81 LMNA (0.52) HSD17B10KMT2ALMNAGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2999469-A1 PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION Bayer Pharma Aktiengesellschaft (DE) 2016-03-30 EP disclosed
WO-2014187744-A1 PHARMACEUTICAL COMPOSITION AND THE USE THEREOF, AND APPLICATION REGIME OF SAID PHARMACEUTICAL COMPOSITION FOR ON-DEMAND CONTRACEPTION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-11-27 WO disclosed
EP-1597228-A2 SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS Sanofi-Aventis Deutschland GmbH (DE) 2005-11-23 EP disclosed
EP-1534689-A1 NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-06-01 EP disclosed
WO-2004072025-A2 SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-26 WO disclosed
WO-2004024702-A1 NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-03-25 WO disclosed